Proteolysis targeting chimeras and related molecules that induce targeted protein degradation by the ubiquitin-proteasome system represents a new therapeutic modality and are the focus of great interest , owing to potential advantages over traditional occupancy based inhibitors with respect to dosing ,side effects , drug resistance and modality under undraggable charges. Protein degradation plays a central role in many cellular functions. Misfolded and damaged protein are removed from the cell to avoid toxicity. The concentration of regulatory proteins are adjusted by degradation at the appropriate time. Both foreign and native proteins are digested into small peptides as a part of the adaptive immune response. In eukaryotic cells, and ATP dependent protease called the proteasome is responsible for much of this proteolysis. Targeted protein degradation has emerged as a transformative the reputic strategy that allows selective removal of disease causing proteins rather than simply inhibiting their function. TPD represents a paradigm shift in drug discovery and expected to revolutionize treatment for cancer neurodegradation, infectious diseases and drug resistance conditions.